Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for adults with type 1 and type 2 diabetes. It begins working within 12 minutes, mimicking the body's natural insulin response. Cipla aims to improve diabetes management accessibility across India with this partnership.
